Bristol-Myers Squibb Company. (NYSE:BMY) Guggenheim Securities Radiopharmaceuticals Day May 13, 2024 11:00 AM ET Company Participants Ben Hickey - President RayzeBio, Head of Mirati Conference Call Participants Unidentified Analyst Alright, Ben, let's continue here with Ben Hickey now from Bristol. Welcome. Thanks for joining us today. And so, yes, before we start with the fireside chat here, yes could you just introduce yourself and talk a bit about your role at Bristol. First of all, good to see you. Ben ...

Bristol-Myers Squibb Company. (NYSE:BMY) Guggenheim Securities Radiopharmaceuticals Day May 13, 2024 11:00 AM ET Company Participants Ben Hickey - President RayzeBio, Head of Mirati Conference Call Participants Unidentified Analyst Alright, Ben, let's continue here with Ben Hickey now from Bristol. Welcome. Thanks for joining us today. And so, yes, before we start with the fireside chat here, yes could you just introduce yourself and talk a bit about your role at Bristol. First of all, good to see you. Ben ...

Bristol Myers (BMY) recently announced that a late-stage study, seeking to expand the label of its cancer combination drug, Opdivo (nivolumab) and Yervoy (ipilimumab), failed to meet the primary endpoint of progression-free survival in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).The phase III CheckMate -73L study evaluated Opdivo with concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoycompared with CCRT followed by AstraZeneca’s (AZN) Imfinzi (durvalumab) in 92 ...

Bad news can be good news for an enterprising investor with a longer time horizon than the market's immediate reaction.About once every 90 days, publicly traded companies have to face their shareholders and let them know how their businesses have performed over the past quarter. Those earnings releases often bring with them all sorts of news that can move the market.Sometimes that news is bad, which can knock a company's stock down. Yet that can provide an opportunity for investors to buy shares at a bargai ...

Should investors brace for a dividend cut?Bristol Myers Squibb (BMY 0.45%) pays investors an attractive dividend, which yields an incredibly high rate of 5.5%. That's nearly four times the S&P 500 average of 1.4%. At such a high rate, investing approximately $18,200 would be enough to generate $1,000 in annual dividends from the stock.However, as is the case with many high-yielding stocks, Bristol Myers' dividend comes with some risk. The company's growth has been a concern for investors, and recently, its ...

Key PointsA dismal report from CVS has sent shares plunging, but they already look to have put in a low. Bristol-Myers is experiencing something similar, with a big day of gains yesterday boding well for next week. TripAdvisor shares are still recovering from Wednesday's shock and hold the most risk but also the most reward. 5 stocks we like better than CVS HealthSavvy stock investors often look for bargains using the Relative Strength Index (RSI). This technical tool evaluates a stock's performance over th ...

They offer plenty of upside and solid dividend growth.It's easy to find stocks that are lagging broader equities, even in a bull market like the one we're currently in. It's harder to find beaten-down stocks that still look worth buying and holding onto for a while. Some corporations are condemned to deliver subpar financial results and stock market performances practically in perpetuity.Thankfully, Bristol Myers Squibb (BMY 2.45%) and Pfizer (PFE 1.19%), two drugmakers that are failing to keep pace with br ...

Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel for transfusion-dependent beta-thalassemia in mid-2024 and additional updates by year-end 2024 Presenting pre-clinical data at ASGCT on in vivo capabilities to support development of transformative in vivo gene editing medicines Strong finan ...

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE:BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The extension also has options to extend the collaboration for up to an additional two years. Under the collaboration, ...

A federal judge in New Jersey on Monday rejected Johnson & Johnson and Bristol Myers Squibb's legal challenges to the Biden administration's Medicare drug price negotiations, ruling that the program is constitutional. The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the price talks. The ruling also weakens the pharmaceutical industry's strategy of seeking split decisions in lower courts scattered across the U.S., which could escalate the issue to ...